Surgery-Based Treatment and Prognostic Factors in Limited-Stage Small Cell Lung Cancer

Mingbo Wang's retrospective cohort study analyzes clinical data from 103 patients with limited-stage small cell lung cancer (LS-SCLC) who underwent complete R0 resection and perioperative adjuvant therapy at the Fourth Hospital of Hebei Medical University from 2014 to 2019. The dataset includes disease-free survival (DFS) and overall survival (OS) outcomes, with a median follow-up of 64 months. Multivariable Cox regression was used to identify independent prognostic factors.

Use Cases

• Modeling survival outcomes based on pathological Tumor-Node-Metastasis (pTNM) stage.
• Investigating the association between adjuvant chemotherapy plus thoracic radiotherapy and improved survival.
• Analyzing the impact of postoperative brain metastasis as a post-treatment progression event on patient outcomes.

Strengths

• Includes data from 103 highly selected patients with complete R0 resection.
• Provides median overall survival (81 months) and disease-free survival (50 months) figures.
• Reports 5-year OS (58.3%) and DFS (50.5%) rates with statistical significance (P-values).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single institution (Fourth Hospital of Hebei Medical University) and a highly selected cohort, which may limit generalizability.

Provenance

Source

Mingbo Wang, Fourth Hospital of Hebei Medical University

Collection Method

Retrospective analysis of clinical data.

Time Range

2014 to 2019

Freshness

Last updated 2026-05-13 04:45:04; freshness should be verified.

Geography

Fourth Hospital of Hebei Medical University, China